Author Interviews, Boehringer Ingelheim, Cancer Research / 12.12.2016
Mesothelioma: Nintedanib Plus Chemotherapy Demonstrated Improved Progression-Free Survival
MedicalResearch.com Interview with:
Professor Giorgio V. Scagliotti
Chair of the Department of Oncology
University of Torino,Italy
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: LUME-Meso II is an international study designed to evaluate the safety and efficacy of nintedanib plus pemetrexed/cisplatin, followed by nintedanib versus placebo plus pemetrexed/cisplatin, followed by placebo, for the treatment of patients with unresectable malignant pleural mesothelioma (MPM).
MPM is a rare cancer that affects the cells that make up the mesothelium of the pleura – the lining or membrane that covers and protects the lungs. It represents less than 1% of all cancers and is often related to long-term asbestos exposure with some suffering from malignant mesothelioma.
A significant improvement in progression-free survival (PFS), the study’s primary endpoint, was observed for patients receiving nintedanib plus chemotherapy compared to patients receiving placebo plus chemotherapy.
(more…)